AstraZeneca divests global rights to Movantik

25 February 2020 07:00 GMT
 

License to RedHill Biopharma supports AstraZeneca’s focus on main therapy areas
 

AstraZeneca has agreed to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). Movantik is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC).

Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: “This divestment supports our strategy to realise value from medicines in our portfolio that are mature or outside our current scope to enable reinvestment in our main therapy areas. Movantik is an important established medicine and the divestment to RedHill will ensure its continued availability for patients.”

As part of the agreement, AstraZeneca will continue to manufacture and supply Movantik to RedHill during a transition period. In 2015, AstraZeneca entered into a co-commercialisation agreement with Daiichi Sankyo, Inc. for Movantik in the US, which will be transferred to RedHill.

Financial considerations

RedHill will make an upfront payment of $52.5m to AstraZeneca on closing and a further non-contingent payment of $15m in 2021. Income arising from the upfront payment, offset by a charge for derecognition of the associated intangible asset, and the future payment will be reported in AstraZeneca’s financial statements within Other Operating Income & Expense. In 2019, Movantik generated sales of $96m in the US. The divestment is expected to complete in the first quarter of 2020, subject to customary closing conditions and regulatory clearances. Upon completion, the agreement will not impact the Company’s financial guidance for 2020.

Movantik

Movantik is a once-daily oral PAMORA approved by the US Food and Drug Administration for the treatment of OIC in adult patients with chronic non-cancer pain. Movantik欧洲杯2020赛程 was licensed from Nektar Therapeutics in 2009. It was developed using Nektar’s oral small-molecule polymer conjugate technology. In 2016, AstraZeneca divested the rights in Europe to ProStrakan Group (now KKI) and the rights in Canada and Israel to Knight Therapeutics.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit russiaaudit.com and follow the Company on Twitter @.

 

Contacts

Media Relations

 

 

欧洲杯2020赛程Gonzalo Viña

 

+44 203 749 5916

Rob Skelding

Oncology

+44 203 749 5821

Rebecca Einhorn

Oncology

+1 301 518 4122

Matt Kent

BioPharmaceuticals

+44 203 749 5906

Angela Fiorin

欧洲杯2020赛程BioPharmaceuticals

+44 1223 344 690

Jennifer Hursit

Other

欧洲杯2020赛程+44 203 749 5762

Christina Malmberg Hägerstrand

Sweden

+46 8 552 53 106

欧洲杯2020赛程Michele Meixell

US

+1 302 885 2677

     

Investor Relations

 

 

Thomas Kudsk Larsen

 

+44 203 749 5712

Henry Wheeler

Oncology

欧洲杯2020赛程+44 203 749 5797

欧洲杯2020赛程Christer Gruvris

欧洲杯2020赛程BioPharmaceuticals

(Cardiovascular, Metabolism)

+44 203 749 5711

Nick Stone

欧洲杯2020赛程BioPharmaceuticals (Renal) Environmental, Social and Governance

+44 203 749 5716

Josie Afolabi

BioPharmaceuticals (Respiratory)

欧洲杯2020赛程+44 203 749 5631

欧洲杯2020赛程Tom Waldron

Other medicines

欧洲杯2020赛程+44 7385 033 717

欧洲杯2020赛程Craig Marks

Finance

Fixed income

+44 7881 615 764

Jennifer Kretzmann

欧洲杯2020赛程Corporate access

Retail investors

欧洲杯2020赛程+44 203 749 5824

欧洲杯2020赛程US toll-free

 

欧洲杯2020赛程+1 866 381 72 77

 

Adrian Kemp
Company Secretary
AstraZeneca PLC

 

tags

  • Corporate and financial
  • Partnering